Boehringer Ingelheim Expands Use of Medidata’s Rave Electronic Data Capture Technology to Clinical Trials

Collaboration focuses on industry-leading technologies and decentralized clinical trial capabilities to increase research efficiency and patient engagement

NEW YORK, October 27, 2022–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company, and Boehringer Ingelheim today announced a renewed five-year collaboration in the broad field of electronic data capture (EDS). This renewed agreement aims to expand the use of the SED Rave system in Boehringer Ingelheim clinical trials worldwide and includes myMedidata, Medidata’s suite of innovative patient-facing technologies focused on improving their diversity and of the patient-oriented approach during decentralized clinical trials (DCTs).

This agreement enables Boehringer Ingelheim to strengthen its patient engagement strategy in meaningful ways by leveraging Medidata’s scalable, patient-centric capabilities, including the myMedidata patient portal, a single-destination, web-based platform that enables electronic consent, electronic clinical outcome assessments (eCOA) and patient/researcher visits via video conferencing through myMedidata LIVE.

“As industry leaders, Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients,” said Anthony Costello, CEO of Medidata’s Patient Cloud Division. “Boehringer Ingelheim’s global reach in various therapeutic areas and the scalable capabilities of myMedidata and the rest of Medidata’s Clinical Cloud platform are a perfect fit. By joining forces, we will be able to rapidly improve patient diversity and access to a broad set of clinical programs. »

Medidata’s decentralized clinical trials program – the industry’s only scalable end-to-end offering – is helping to revolutionize the way people transmit data, the way drugs are shipped to patients, and the way they are managed and managed. monitoring of clinical trial data. These remote technologies also and above all create possibilities for optimizing access, inclusiveness and involvement of patients in various geographical areas and opportunities for strengthening their diversity during clinical trials.

Boehringer Ingelheim has relied on Medidata technologies, be it the Rave SED (electronic data capture) system, TSDV (targeted source data verification), Coder or Safety Gateway. Boehringer Ingelheim is also exploring Medidata’s AI Intelligent Trials system to deliver in-depth analytics and improve the speed, success and quality of clinical trials. It benefits from Medidata’s Rave imaging technology through contracted services with the company’s imaging providers.

Medidata is a wholly owned subsidiary of Dassault Systèmes. With its 3DEXPERIENCE platform, it is uniquely positioned to drive the digital transformation of life sciences in the era of personalized medicine, using the first end-to-end business and science platform. , from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences and creating hope for millions of patients. Medidata helps provide evidence and insights that enable pharmaceutical, biotechnology, diagnostics, and medical device companies, as well as academic researchers, to accelerate value creation, mitigate risk, and optimize outcomes. More than one million registered users, representing more than 2,000 customers and partners, access the world’s most trusted platform for obtaining commercial, observational and clinical development data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York and has offices around the world to meet the needs of its customers. For more information, visit www.medidata.com and follow us on Twitter at @medidata.

About Dassault Systemes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We offer companies and individuals collaborative 3D virtual environments to imagine sustainable innovations. By creating real-world virtual twin experiences through our applications and our 3DEXPERIENCE® platform, our customers push the boundaries of innovation, learning and production in favor of a more sustainable world, for the benefit patients, citizens and consumers. DASSAULT Systèmes brings value to more than 300,000 customers of all sizes, in all sectors and in more than 140 countries. For more information, visit www.3ds.com

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are trademarks or registered trademarks of Dassault Systèmes, a ” French European Company (Versailles Trade Register No. B 322 306 440), or its subsidiaries in the United States and/or other countries.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20221027005030/en/

contacts

Tom Paulella
Director General of Commercial Affairs and Communication
+1-848-203-7596
[email protected]

Paul Oestreicher
Director of External Communications
+1-917-522-4692
[email protected]

Leave a Comment